Press Resease

Real World Evidence Solutions Market by Component (Data Sets and Services), by Therapeutic Area (Oncology, Cardiovascular Disease, Neurology, Immunology, and Others), and by End-Users (Pharmaceutical and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2026

Published Date: 17-Sep-2018 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3365 Status : Published

Global real world evidence solutions market expected to generate revenue of around USD 1,954.00 million by end of 2026, growing at a CAGR of around 13.8% between 2018 and 2026. The scenario of data collection is changing day by day. The demographic development and profile together with rising treatment potential leads to a lot of challenges to augment the productivity of healthcare.

Description

The report covers forecast and analysis for the real world evidence solutions market on a global and regional level. The study provides historic data for 2016 and 2017 along with a forecast from 2018 to 2026 based on revenue (USD Million). The study includes drivers and restraints for the real world evidence solutions market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the real world evidence solutions market on a global level.

In order to give the users of this report a comprehensive view of the real world evidence solutions market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein component, therapeutic areas, and end-user segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Real World Evidence Solutions

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, technology and regional expansion of major participants involved in the market on global and regional basis. Moreover, the study covers price trend analysis, component portfolio of various companies according to region.

The study provides a decisive view of the real world evidence solutions market by segmenting the market based on component, therapeutic areas, end-users, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2026. Based on component, the market is segmented into data set and services. The data set segment is further sub-segmented into clinical setting data, claims data, pharmacy data, and patient powered data. On the basis of the therapeutic area, the global market is segmented into oncology, cardiovascular disease, neurology, immunology, and others. Based on end-users, the market is segmented as pharmaceutical and medical device companies, healthcare payers, healthcare providers, and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further division into major countries including the U.S., Rest of North America, U.K., Germany, France, Italy, Spain, Rest of Europe, China, Japan, India, southeast Asia, Rest of Asia Pacific, Brazil, Rest of Latin America, GCC Countries, South Africa and Rest of the Middle East and Africa. This segmentation includes demand for real world evidence solutions market based on individual component, therapeutic areas, and end-user in all the regions and countries.

The report also includes detailed profiles of end players such as IQVIA, International Business Machines Corporation, ICON, PAREXEL, Pharmaceutical Product Development, Optum, Cognizant, Oracle, SAS, Syneos Health, Clinigen Group, Palantir Technologies, and Flatiron Health, among others.

This report segments the global real world evidence solutions market as follows:

Global Real World Evidence Solutions Market: Component Segment Analysis

  • Data Sets  
    • Clinical Setting Data
    • Claims Data
    • Pharmacy Data
    • Patient Powered Data
  • Services 

Global Real World Evidence Solutions Market: Therapeutic Area Segment Analysis

  • Oncology
  • Cardiovascular Disease
  • Neurology
  • Immunology
  • Others Therapeutic Areas

Global Real World Evidence Solutions Market: End-user Segment Analysis

  • Pharmaceutical and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Others

Global Real World Evidence Solutions Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Real World Evidence Solutions Market, 2017 - 2026 (USD Million)
    • 2.2. Global Real World Evidence Solutions Market: snapshot
  •  
  • Chapter 3. Real World Evidence Solutions Market- Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Real World Evidence Solutions Market drivers: impact analysis
      • 3.2.2. Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
      • 3.2.3. Shift From Volume- to Value-Based Care
      • 3.2.4. Delays in Drug Development and the Subsequent Increase in Development Costs
    • 3.3. Market Restraints
      • 3.3.1. Global Real World Evidence Solutions Market restraints: impact analysis
      • 3.3.2. Reluctance to Rely on Real-World Studies
    • 3.4. Opportunities
      • 3.4.1. Growth Opportunities in Emerging Markets
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by Component segment
      • 3.6.2. Market attractiveness analysis, by Therapeutic areas segment
      • 3.6.3. Market attractiveness analysis, by End-users segment
      • 3.6.4. Market attractiveness analysis, by Regional segment
  •  
  • Chapter 4. Global Real World Evidence Solutions Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Real World Evidence Solutions Market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  •  
  • Chapter 5. Global Real World Evidence Solutions Market- Component Segment Analysis
    • 5.1. Global Real World Evidence Solutions Market: Component overview
      • 5.1.1. Global Real World Evidence Solutions Market revenue share, by Component, 2017 and 2026
    • 5.2. Data Set
      • 5.2.1. Global Real World Evidence Solutions Market for Data Set Market, 2017 - 2026 (USD Million)
      • 5.2.2. Global Real World Evidence Solutions Market for Clinical Setting Data, 2017 - 2026 (USD Million)
      • 5.2.3. Global Real World Evidence Solutions Market for Claims Data, 2017 - 2026 (USD Million)
      • 5.2.4. Global Real World Evidence Solutions Market for Pharmacy Data, 2017 - 2026 (USD Million)
      • 5.2.5. Global Real World Evidence Solutions Market for Patient Powered Data, 2017 - 2026 (USD Million)
    • 5.3. Services
      • 5.3.1. Global Real World Evidence Solutions Market for Services Market, 2017 - 2026 (USD Million)
  •  
  • Chapter 6. Global Real World Evidence Solutions Market- Therapeutic areas Segment Analysis
    • 6.1. Global Real World Evidence Solutions Market: Therapeutic areas overview
      • 6.1.1. Global Real World Evidence Solutions Market revenue share, by Therapeutic areas, 2017 and 2026
    • 6.2. Oncology
      • 6.2.1. Global Real World Evidence Solutions Market for Oncology market, 2017 - 2026 (USD Million)
    • 6.3. Cardiovascular Diseases
      • 6.3.1. Global Real World Evidence Solutions Market for Cardiovascular Diseases market, 2017 - 2026 (USD Million)
    • 6.4. Neurology
      • 6.4.1. Global Real World Evidence Solutions Market for Neurology market, 2017 - 2026 (USD Million)
    • 6.5. Neurology
      • 6.5.1. Global Real World Evidence Solutions Market for Neurology market, 2017 - 2026 (USD Million)
    • 6.6. Immunology
      • 6.6.1. Global Real World Evidence Solutions Market for Neurology market, 2017 - 2026 (USD Million)
    • 6.7. Others
      • 6.7.1. Global Real World Evidence Solutions Market for Neurology market, 2017 - 2026 (USD Million)
  •  
  • Chapter 7. Global Real World Evidence Solutions Market- End-user Segment Analysis
    • 7.1. Global Real World Evidence Solutions Market: End-user overview
      • 7.1.1. Global Real World Evidence Solutions Market revenue share, by End-user, 2017 and 2026
    • 7.2. Pharmaceutical and Medical Device Companies
      • 7.2.1. Global Real World Evidence Solutions Market for Pharmaceutical and Medical Device Companies 2017 - 2026 (USD Million)
    • 7.3. Healthcare Payers
      • 7.3.1. Global Real World Evidence Solutions Market for Healthcare Payers 2017 - 2026 (USD Million)
    • 7.4. Healthcare Providers
      • 7.4.1. Global Real World Evidence Solutions Market for Healthcare Providers, 2017 - 2026 (USD Million)
    • 7.5. Other End Users
      • 7.5.1. Global Real World Evidence Solutions Market for Other End Users, 2017 - 2026 (USD Million)
  •  
  • Chapter 8. Global Real World Evidence Solutions Market- Regional Segment Analysis
    • 8.1. Global Real World Evidence Solutions Market: regional overview
      • 8.1.1. Global Real World Evidence Solutions Market revenue share, by region, 2017 and 2026
    • 8.2. North America
      • 8.2.1. North America Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
      • 8.2.2. North America Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
      • 8.2.3. North America Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.2.4. U.S.
        • 8.2.4.1. U.S. Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.2.4.2. U.S. Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.2.4.3. U.S. Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.2.5.2. Rest of North America Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.2.5.3. Rest of North America Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
      • 8.3.2. Europe Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
      • 8.3.3. Europe Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.3.4. U.K.
        • 8.3.4.1. U.K. Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.3.4.2. U.K. Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.3.4.3. U.K. Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.3.5.2. Germany Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.3.5.3. Germany Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.3.6.2. France Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.3.6.3. France Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.3.7. Italy
        • 8.3.7.1. Italy Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.3.7.2. Italy Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.3.7.3. Italy Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.3.8. Spain
        • 8.3.8.1. Spain Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.3.8.2. Spain Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.3.8.3. Spain Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.3.9. Rest of Europe
        • 8.3.9.1. Rest of Europe Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.3.9.2. Rest of Europe Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.3.9.3. Rest of Europe Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
      • 8.4.2. Asia Pacific Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
      • 8.4.3. Asia Pacific Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.4.4.2. China Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.4.4.3. China Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.4.5.2. Japan Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.4.5.3. Japan Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.4.6.2. India Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.4.6.3. India Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.4.7. Southeast Asia
        • 8.4.7.1. Southeast Asia Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.4.7.2. Southeast Asia Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.4.7.3. Southeast Asia Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
      • 8.5.2. Latin America Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
      • 8.5.3. Latin America Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.5.4.2. Brazil Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.5.4.3. Brazil Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.5.5.2. Rest of Latin America Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.5.5.3. Rest of Latin America Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
    • 8.6. Middle East and Africa
      • 8.6.1. Middle East and Africa Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
      • 8.6.2. Middle East and Africa Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
      • 8.6.3. Middle East and Africa Real World Evidence Solutions Market revenue, by end user, 2017 - 2026 (USD Million)
      • 8.6.4. GCC Countries
        • 8.6.4.1. GCC Countries Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.6.4.2. GCC Countries Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.6.4.3. GCC Countries Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.6.5. South Africa
        • 8.6.5.1. South Africa Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.6.5.2. South Africa Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.6.5.3. South Africa Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
      • 8.6.6. Rest of Middle East and Africa
        • 8.6.6.1. Rest of Middle East and Africa Real World Evidence Solutions Market revenue, by Component, 2017 - 2026 (USD Million)
        • 8.6.6.2. Rest of Middle East and Africa Real World Evidence Solutions Market revenue, by Therapeutic areas, 2017 - 2026 (USD Million)
        • 8.6.6.3. Rest of Middle East and Africa Real World Evidence Solutions Market revenue, by end-users, 2017 - 2026 (USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Oracle
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Therapy portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Flatiron
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Therapy portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Clinigen Group plc.
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Therapy portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. PAREXEL International Corporation
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Therapy portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. IQVIA Holdings Inc.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Therapy portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Syneos Health, Inc.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Therapy portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Optum, Inc.
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Therapy portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Cognizant
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Therapy portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Palantir Technologies Inc.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Therapy portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Pharmaceutical Product Development, LLC.
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Therapy portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. Icon Plc.
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Therapy portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. SAS Institute Inc.
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Therapy portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments
    • 9.13. IBM Corporation
      • 9.13.1. Overview
      • 9.13.2. Financials
      • 9.13.3. Therapy portfolio
      • 9.13.4. Business strategy
      • 9.13.5. Recent developments
    • 9.14. HealthCore Inc.
      • 9.14.1. Overview
      • 9.14.2. Financials
      • 9.14.3. Therapy portfolio
      • 9.14.4. Business strategy
      • 9.14.5. Recent developments

Methodology

Free Analysis

The healthcare industry is constantly in a surge to improve efficiency and throughput by reducing costs and waste, thus automation of labor-intensive tasks can be a significant part of a strategy for performance enhancement. Healthcare providers are facing the challenges with increasing number of patients regarding managing inventory, optimizing scheduled time for appointments, supporting digitization of patient records, and performing billing and claims processing. In order to reduce these operational challenges, the maximum number of healthcare providers are embracing automation to decrease these problems and drive enhanced efficiency and growth of the healthcare sector.

 The rising geriatric population and the subsequent increase in the prevalence of chronic diseases will significantly drive the market during the forecast period. Geriatric population is majorly suffering from the chronic diseases but these elderly people are often excluded from clinical trials. The real world evidence can be significantly used to understand how the excluded individuals react to a drug. That will provide a much broader insight into the how a product will affect the heterogeneous patient population outside of the clinical trial setting. This broader insight will help in identification of populations with enhanced benefit/risk, minimization of the number of patients exposed to less efficacious therapy, and much more, which will significantly propel the growth of real world evidence solutions market over the forecast period

Global Real World Evidence Solutions
 
The global real world evidence solutions market is segmented on the basis of the component, therapeutic areas, and end-users. Based on the component, the market is segmented into data set and services. The data set segment is further sub-segmented into clinical setting data, claims data, pharmacy data, and patient-powered data. Increasing need for integrated and development of precision medications will significantly boost the market during the forecast period. On the basis of a therapeutic area, the global market is segmented into cardiovascular disease, oncology, immunology, neurology, and others. Based on end-users, the market is segmented as healthcare providers, pharmaceutical and medical device companies, healthcare payers, and others. Pharmaceutical and medical device companies segment contribute for the significant share in global real world evidence solutions market owing to increasing adoption of RWE in pharmaceutical and medical device companies. 

North America held a dominant share of the international market for real world evidence solutions market in 2017 and region is projected to continue with its regional supremacy over the forthcoming years as well. The growth of this regional market is attributed with the favorable government policies and increasing clinical trials by the prominent market players. Europe holds the second largest position in the global real world evidence solutions market, owing to rapidly increasing geriatric population and increasing clinical trials for novel drug development in the region. Asia Pacific real world evidence solutions market is projected to grow at a significant CAGR, due to developing healthcare infrastructure and favorable government policies in this region.

Some of the key players in the real world evidence solutions market are IQVIA, International Business Machines Corporation, ICON, PAREXEL, Pharmaceutical Product Development, Optum, Cognizant, Oracle, SAS, Syneos Health, Clinigen Group, Palantir Technologies, and Flatiron Health. 

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com